How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (OTCMKTS:DCTHD) issued its quarterly earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share for the quarter, beating the consensus estimate of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. During the same period in the previous year, the business earned ($686.00) EPS.

When did Delcath Systems' stock split?

Delcath Systems shares reverse split on the morning of Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

OTCMKTS:DCTHD

Delcath Systems (DCTHD) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free DCTHD Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $4.26
▼
$5.03
50-Day Range: N/A
52-Week Range: $1.22
▼
$63,000.00

Volume: 335,142 shs
Average Volume: 771 shs
Market Capitalization: $187,800.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Headlines

Get Delcath Systems alerts:

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Delcath Systems Stock (OTCMKTS:DCTHD)

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

DCTHD Stock News Headlines

March 21, 2024 | gurufocus.com

Director Gil Aharon Acquires 26,882 Shares of Delcath Systems Inc (DCTH)

December 30, 2023 | benzinga.com

Delcath Systems Stock (NASDAQ:DCTH) Insider Trades

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

December 30, 2023 | benzinga.com

Delcath Systems Stock (NASDAQ:DCTH) Dividends: History, Yield and Dates

August 31, 2023 | thestreet.com

Delcath Liver Tumor Data Improve

August 15, 2023 | msn.com

Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy

August 11, 2023 | msn.com

Delcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFA

August 9, 2023 | msn.com

Delcath Systems GAAP EPS of -$0.58 beats by $0.02, revenue of $0.5M misses by $0.24M

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

July 9, 2023 | thestreet.com

Delcath Readies Pivotal Trial Results

June 19, 2023 | forbes.com

Best iPad POS Systems Of 2023

May 24, 2023 | msn.com

HC Wainwright & Co. Reiterates Delcath Systems (DCTH) Buy Recommendation

May 15, 2023 | bbc.co.uk

What is the digestive system?

May 12, 2023 | thestreet.com

Delcath: Safety Questions Behind FDA Delay

March 27, 2023 | finance.yahoo.com

Delcath Systems Announces up to $85 Million Financing

March 27, 2023 | markets.businessinsider.com

Delcath Systems Inc. Q4 Loss increases, misses estimates

March 27, 2023 | finance.yahoo.com

Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 27, 2023 | markets.businessinsider.com

Delcath Announces FDA's Acceptance Of NDA Resubmission Of Hepzato Kit

February 16, 2023 | markets.businessinsider.com

Delcath Systems Announces Resubmission Of NDA For Hepzato Kit

December 15, 2022 | gurufocus.com

An Insider Just Bought Shares of Delcath Systems Inc; Could This Stock Be a Value Opportunity?

November 8, 2022 | seekingalpha.com

Delcath Systems slips despite Q3 beat

September 10, 2022 | seekingalpha.com

DCTH Delcath Systems, Inc.

August 10, 2022 | markets.businessinsider.com

Delcath Systems Inc. Q2 Loss increases, misses estimates

July 27, 2022 | markets.businessinsider.com

Delcath Systems to Host Second Quarter 2022 Results

March 15, 2022 | benzinga.com

Delcath Systems to Host Fourth Quarter and Full Year 2021 Results

February 4, 2022 | benzinga.com

Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver

December 2, 2021 | benzinga.com

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

See More Headlines

Receive DCTHD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2016
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Surgical & Medical Instruments
Sub-Industry: N/A
Current Symbol: OTCMKTS:DCTHD
Previous Symbol: NASDAQ:DCTH
CUSIP: N/A
CIK: N/A
Web: www.delcath.com
Phone: 212-489-2100
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,220,000.00
Net Margins: -1,546.38%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -343.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.53
Quick Ratio: 0.50

Sales & Book Value

Annual Sales: $3.41 million
Price / Sales: 0.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1,036.00) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 40,000
Free Float: N/A
Market Cap: $187,800.00
Optionable: Not Optionable
Beta: -0.03

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Roger G. Stoll Ph.D. (Age 74)
Chairman of the Board
Jennifer K. Simpson Ph.D. (Age 48)
President, Chief Executive Officer, Director
Barbra C. Keck (Age 39)
Chief Financial Officer, Secretary
John Purpura (Age 55)
Executive Vice President - Global Head of Operations
Simon C. Pedder Ph.D. (Age 56)
Director
William Dodge Rueckert (Age 64)
Independent Director
Marco Taglietti M.D. (Age 57)
Independent Director

Key Competitors

View All Competitors

DCTHD Stock Analysis - Frequently Asked Questions

How were Delcath Systems' earnings last quarter?: Delcath Systems, Inc. (OTCMKTS:DCTHD) issued its quarterly earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share for the quarter, beating the consensus estimate of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. During the same period in the previous year, the business earned ($686.00) EPS.
When did Delcath Systems' stock split?: Delcath Systems shares reverse split on the morning of Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

This page (OTCMKTS:DCTHD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Delcath Systems (DCTHD) Stock Price, News & Analysis

About Delcath Systems Stock (OTCMKTS:DCTHD)

DCTHD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

DCTHD Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info